Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
-
Shares outstanding
-
41.1M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
20.2M
-
Shares change
-
-1.43M
-
Total reported value, excl. options
-
$19.4M
-
Value change
-
-$1.27M
-
Number of buys
-
6
-
Number of sells
-
-9
-
Price
-
$0.96
Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q1 2023
23 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q1 2023.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.2M shares
of 41.1M outstanding shares and own 49.21% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (11.1M shares), BAKER BROS. ADVISORS LP (2.59M shares), Artal Group S.A. (2.26M shares), Redmile Group, LLC (1.61M shares), Point72 Asset Management, L.P. (1.41M shares), RENAISSANCE TECHNOLOGIES LLC (380K shares), MORGAN STANLEY (284K shares), AXA S.A. (282K shares), MILLENNIUM MANAGEMENT LLC (127K shares), and Forefront Analytics, LLC (75.6K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.